Search clinical trials for: Ranibizumab 6 MG/ML [Lucentis]

Total 1669 results

Faculty Hospital Kralovske Vinohrady

Withdrawn

Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation (BEY-RAP)

Wet Macular Degeneration

Czechia
Adynxx, Inc.
National Institute on Drug Abuse (NIDA)

Withdrawn

Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Mastectomy in Patients With High PCS Scores

Pain, Postoperative
Renmin Hospital of Wuhan University

Recruiting

Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion (UWFA-RVO-ME)

Macular Edema | Retinal Vein Occlusion

China
Bernardete Pessoa MD

Completed

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema (SWITCH)

Diabetic Retinopathy | Diabetic Macular Edema
Medical University of Vienna

Completed

Ranibizumab in Patients With Branch Retinal Vein Occlusion

Retinal Vein Occlusion

Austria
Sun Yat-sen University

Terminated

Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy

Polypoidal Choroidal Vasculopathy

China
Centro Hospitalar do Porto

Completed

Effect of the Vitreous in Response to Intravitreal Injections of Ranibizumab for the Treatment of Diabetic Macular Edema (DEVITRA)

Diabetic Macular Edema

Portugal
Adynxx, Inc.

Withdrawn

Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Knee Replacement in Patients With High PCS Scores

Pain, Postoperative

United States
Alcon Research

Completed

WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination

Age Related Macular Degeneration
Adynxx, Inc.

Completed

Study to Evaluate Safety/Efficacy of a Single Preop Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery

Post-surgical Pain

United States
Ural State Medical University
Ural Institute of Cardiology; De Haar Research Foundation

Terminated

Ranibizumab and the Risk of Arterial Thromboembolic Events (RATE)

Coronary Artery Disease | Cerebrovascular Disorders | Age-related Macular Degeneration

Netherlands, Russian Federation
Hoffmann-La Roche

Recruiting

A Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Chinese Patients With Neovascular Age-Related Macular Degeneration

Neovascular Age Related Macular Degeneration | nAMD

China
NPO Petrovax

Completed

Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI

Acute Respiratory Infection

Russian Federation
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Unknown

601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)

Branch Retinal Vein Occlusion

China
Genentech, Inc.

Completed

A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO) (BRAVO)

Macular Edema | Retinal Vein Occlusion
Genentech, Inc.

Completed

A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE) (CRUISE)

Macular Edema | Retinal Vein Occlusion
Zagazig University
Cairo University

Completed

Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity

Retinopathy of Prematurity | Ranibizumab | Retina Disease

Egypt
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Unknown

601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)

Central Retinal Vein Occlusion

China
University of Illinois at Chicago
Genentech, Inc.

Withdrawn

Lucentis for New Onset Neovascular Glaucoma (NVG)

Glaucoma | Neovascular Glaucoma | New Onset Glaucoma | New Onset Neovascular Glaucoma
Hoffmann-La Roche

Completed

A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration (Archway)

Neovascular Age-Related Macular Degeneration

United States
Adynxx, Inc.

Completed

Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery

Postsurgical Pain

United States
Charles C Wykoff, PhD, MD
Genentech, Inc.

Completed

Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab (T-REX)

Macular Degeneration

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema (DIVERSE)

Diabetic Retinopathy

Germany
The New York Eye Cancer Center
Genentech, Inc.

Completed

High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy

Radiation Retinopathy

United States
Genentech, Inc.

Completed

An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)

Macular Edema | Retinal Vein Occlusion
Quark Pharmaceuticals
Pfizer

Completed

Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study). (MONET)

Age Related Macular Degeneration

Spain, Korea, Republic of, Turkey, Taiwan, United States, Israel, Austria, Philippines, Denmark, Hong Kong, India
Novartis Pharmaceuticals

Completed

A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients (RIVAL)

Age-Related Macular Degeneration

Australia
Vista Klinik

Completed

SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia

Age Related Macular Degeneration | Choroidal Neovascularization

Switzerland
Novartis Pharmaceuticals

Completed

Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration (TIDE AMD)

Wet Age-Related Macular Degeneration

Germany
Arshad Khanani
Genentech, Inc.

Completed

Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME

Diabetic Macular Edema

United States
Novartis Pharmaceuticals

Completed

Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD) (SALUTE)

Age-related Macular Degeneration

Turkey
Manhattan Eye, Ear & Throat Hospital
Genentech, Inc.

Completed

Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy (FVF4140S)

Polypoidal Choroidal Vasculopathy | Pseudoxanthoma Elasticum | Pathological Myopia | Retinal Angiomatous Proliferation | Coats' Disease | Idiopathic Retinal Telangiectasia | Multi-focal Choroiditis | Rubeosis Iridis | Von Hippel Lindau Disease | BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)

United States
Incepta Pharmaceuticals Ltd
Institute for Developing Science and Health Initiatives, Bangladesh

Recruiting

A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema

Macular Degeneration | Retinal Degeneration | Diabetic Retinopathy | Diabetic Macular Edema | Macular Edema | Retinal Disease

Bangladesh
Santen Inc.

Completed

Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects

Age-Related Macular Degeneration

United States, Philippines
The National Retina Institute
Genentech, Inc.

Completed

Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration

Macular Degeneration

United States
Retina Associates of Cleveland, Inc
Genentech, Inc.

Unknown

Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion

Depression | Central Retinal Vein Occlusion | Retinal Vein Occlusion | Venous Retinal Branch Occlusion

United States
Southeast Clinical Research Associates, LLC
Genentech, Inc.

Completed

Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF

Exudative Age Related Macular Degeneration

United States
Lawrence S. Morse, MD
Genentech, Inc.

Completed

Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD) (Antibody)

Age Related Macular Degeneration

United States
David M. Brown, M.D.
Novartis Pharmaceuticals

Terminated

Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration

Age-Related Macular Degeneration

United States
Greater Houston Retina Research
Genentech, Inc.

Completed

Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy. (RRR)

Radiation Retinopathy

United States
Johns Hopkins University
Juvenile Diabetes Research Foundation

Completed

Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study (READ 3)

Diabetic Macular Edema

United States
Alcon Research
Novartis Institutes for BioMedical Research

Terminated

Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration

Age-related Macular Degeneration (AMD)

United States
Hoffmann-La Roche

Active, not recruiting

This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab (Pagoda)

Diabetic Macular Edema

United States
Novartis Pharmaceuticals

Completed

Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) (Camellia)

Central Retinal Vein Occlusion

China, Taiwan, Hong Kong, Philippines, Vietnam, Indonesia, India
Lahey Clinic

Withdrawn

Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD)

Macular Edema
Hoffmann-La Roche

Active, not recruiting

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PAVILION)

Diabetic Retinopathy

United States, Puerto Rico
New England Retina Associates

Withdrawn

Ranibizumab as a Rescue Therapy for Diabetic Macular Edema

Diabetic Macular Edema

United States
Alcon Research

Completed

ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients

Exudative Age-Related Macular Degeneration
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia (Brilliance)

Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)

China, India, Thailand, Hong Kong, Korea, Republic of, Philippines
Mid-Atlantic Retina Consultations, Inc.

Completed

Photodynamic and Pharmacologic Treatment of CNV (PBS)

Macular Degeneration | Choroidal Neovascularization

3

Subscribe